SCHEMBL1614871

SCHEMBL1614871

CCC(CCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)[C@H]2C(C)(C)[C@]12O)CC(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 5/20 0.63
PRKCG P05129 5/20 0.63
PRKD3 O94806 4/20 0.63
PRKCB P05771 4/20 0.63
PRKCH P24723 4/20 0.63
PRKCI P41743 4/20 0.63
PRKCE Q02156 4/20 0.63
PRKCQ Q04759 4/20 0.63
PRKCZ Q05513 4/20 0.63
PRKCD Q05655 4/20 0.63
PRKD1 Q15139 4/20 0.63
USP2 O75604 2/20 0.63
TP53 P04637 2/20 0.63
KDM4E B2RXH2 1/20 0.63
ALDH1A1 P00352 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
CYP3A4 P08684 1/20 0.63
CYP2C9 P11712 1/20 0.63
TSHR P16473 1/20 0.63
NFKB1 P19838 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL82376 0.91 PRKCA (0.63) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL1258697 0.91 PRKCA (0.62) PRKCAPRKCGPRKD3PRKCBPRKCH
Phorbol SCHEMBL28498206 0.88 PRKCA (0.51) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL18399979 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL18622646 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL15725680 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL3516162 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL31074956 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL258513 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL18629158 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040213782-A1 Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure PHARMACIA CORPORATION 2004-10-28 US claimed
WO-2004069181-A2 COMPOSITION FOR THE TREATMENT OF INTRAOCULAR PRESSURE PHARMACIA CORPORATION (US) 2004-08-19 WO claimed
WO-2011044548-A1 THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2011-04-14 WO disclosed
US-20110086895-A1 THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2011-04-14 US disclosed
US-20040213782-A1 Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure PHARMACIA CORPORATION 2004-10-28 US disclosed
WO-2004069181-A2 COMPOSITION FOR THE TREATMENT OF INTRAOCULAR PRESSURE PHARMACIA CORPORATION (US) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086895-A1 THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS PCK2, AK2, SIRT6 PRKCA 275/4885PRKCG 493/4885PRKD3 187/4885
US-20040213782-A1 Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure AQP1, AQP4, AQP3 PRKCA 433/4885PRKCG 332/4885PRKD3 1314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.